SYGNIS announces completion of the X-Pol Biotech acquisition

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.

Capital measures

Heidelberg (euro adhoc) - SYGNIS announces completion of the X-Pol Biotech
·  Registration of the transaction and the previous capital reduction
   (ratio of 8:1) in the Commercial Register
·  New share capital of the Company EUR 9,349,724
·  New ISIN DE000A1RFM03
·  New Ticker symbol LIO1
Heidelberg, December 6, 2012 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN:
DE000A1RFM03, Prime Standard) announced today that the merger with X-Pol Biotech
S.L. (X-Pol) is completed. With the approval of the Annual General Meeting on
October 17, 2012 SYGNIS acquired 100% of the shares of the Spanish X-Pol by way
of a capital increase against contribution in kind. This transaction is
completed with the registration of the capital increase in the Commercial
Register. Thus X-Pol becomes a 100% subsidiary of SYGNIS and SYGNIS' share
capital is increased from EUR 2,103,688 to EUR 9,349,724. After this
transaction, the former shareholders of X-Pol hold 77.5% of SYGNIS shares. The
previous shareholders of SYGNIS now own 22.5% of the new company. No shares were
sold in the capital market.
Before the capital increase, a reduction of SYGNIS' share capital from 
EUR 16,829,504 to EUR 2,103,688 by consolidation of shares in the ratio of 8:1 
was executed. Thereby, eight no par value bearer shares with ISIN DE000A1E9B74 
were merged into one converted no par value bearer share with the new ISIN
DE000A1RFM03. Accordingly, the depositary banks have converted the individual
deposits of SYGNIS shares as they were on December 5, 2012.
If a shareholder did not hold a number of shares divisible by eight, a fraction
of shares, this means a partial entitlement to receive one share (ISIN
DE000A1RFM11), is booked for the shareholder. In order to be converted into full
rights (so-called peak regulation), a corresponding buy or sell order is
required. Each required peak regulation will be executed by the respective
custodian bank by close of business December 21, 2012.
The first listing on December 6, 2012 will be based on the trading price of the
SYGNIS share as of December 5, 2012 and will be correspondingly increased by a
factor of eight.
For further information please contact:

Peter Willinger                    
Tel.: +49 6221 454 836             


About SYGNIS Pharma AG:
SYGNIS Pharma AG (Heidelberg, Germany) is a specialized biotech company listed
in the Prime Standard of the German Stock Exchange (Ticker: LIO1; ISIN:
DE000A1RFM03). So far, the business focus was on the research and development of
innovative therapies for the treatment of diseases of the central nervous
system. After the AXIS 2 study showed no efficacy of AX200 for the treatment of
acute stroke, the program was discontinued. The company is currently continuing
the KIBRA project. With the acquisition of X-Pol, SYGNIS will realign. The
future focus of the company will be in the field of molecular diagnostics.
About X-Pol Biotech, S.L.:
X-Pol Biotech, S.L. (Madrid, Spain) is a biotechnology company created by Prof.
Luis Blanco and GENETRIX in 2008 with a focus on the development of tools and
technologies for the DNA amplification and sequencing market. In July 2012 X-Pol
has licensed its key product, an improved polymerase for amplifying DNA called
"Qualiphi®" to Qiagen for its worldwide commercialisation.
### Disclaimer
Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as forward-
looking, i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered to be
total guarantees since given their very nature they are subject to known and
unknown risks and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS Pharma AG may
deviate greatly from the established conclusions or implied predictions
contained in such statements. SYGNIS does not undertake to publicly update or
revise these statements in the light of new information or future results or for
any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6

end of announcement                               euro adhoc 

company:     SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
sector:      Biotechnology
ISIN:        DE000A1RFM03
language:   English

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: